D.G. Georganopoulou
Papers
1
Total Citations
6
H-Index
1
About
D.G. Georganopoulou is a researcher whose work centers on improving prostate cancer prognosis through innovative biomarker testing and machine learning classification. Their major contribution lies in developing a two-stage classifier that combines PCA3 and PSA proteolytic activity testing to predict biochemical recurrence after radical prostatectomy. This approach addresses a critical clinical need: early recurrence is linked to aggressive disease and higher cancer-specific mortality, yet existing tests often lack predictive precision. By integrating these biomarkers, Georganopoulou’s method enhances risk stratification, potentially guiding more personalized post-surgical monitoring and treatment decisions. Though their most-cited paper (2017) has garnered 6 citations, the work’s impact is underscored by its practical relevance to urologic oncology—a field where accurate recurrence prediction remains challenging. This study exemplifies Georganopoulou’s focus on translating molecular markers into actionable clinical tools, bridging laboratory research and patient care. Their efforts contribute to the broader goal of reducing overtreatment and improving outcomes for prostate cancer patients, making their research a valuable resource for clinicians and scientists seeking to refine prognostic models in oncology.
Research Focus
Key Achievements
Top Papers
- 1